Journal
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
Volume 48, Issue 2, Pages 240-248Publisher
WILEY
DOI: 10.1111/ceo.13668
Keywords
drug therapy; eye; lymphoma; retina
Categories
Funding
- Australian Research Council [FT130101648]
- Australian Research Council [FT130101648] Funding Source: Australian Research Council
Ask authors/readers for more resources
Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate-an anti-metabolite-and rituximab-an anti-human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available